Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

March 15, 2019

FDA Grants Accelerated Approval to Tecentriq-Abraxane Combo for Some TNBC

News

The U.S. Food and Drug Administration has granted accelerated approval to a combination of Tecentriq (atezolizumab) and the chemotherapy Abraxane (nab-paclitaxel) for patients with advanced triple-negative breast cancer, making this ... Read more

March 6, 2019

Imaging Agent May Provide Early Info About Benefits of Hormone Therapies for Breast Cancer

News

A new imaging agent that successfully measures changes in progesterone receptor (PR) levels may be used to determine if a breast cancer patient will respond to hormone therapies targeting ... Read more

February 27, 2019

Sacituzumab Govitecan Shinks Tumors in One of Three Metastatic TNBC Patients, Trial Shows

News

One in three women with metastatic triple-negative breast cancer — all of whom had received at least two prior treatments — saw their tumors shrink after receiving Immunomedics‘ investigational treatment sacituzumab govitecan as ... Read more

February 11, 2019

Margetuximab Helps to Delay Disease Progression in Advanced, HER2-positive Breast Cancers, Phase 3 Trial Shows

News

A combination of MacroGenics‘ HER2 antibody margetuximab and standard chemotherapy is superior to Herceptin (trastuzumab) plus chemotherapy at extending the time to disease progression among advanced and pre-treated breast cancer patients whose ... Read more

October 24, 2018

Sermonix Launches Phase 2 Trial Testing Lasofoxifene in Advanced Breast Cancer Patients with ER Mutations

News

Sermonix is launching a Phase 2 trial to determine if its lead investigational medicine lasofoxifene is better than Faslodex (fulvestrant) at delaying disease progression or death in breast cancer patients ... Read more

May 23, 2017

MCLA-128 Helps Metastatic Breast Cancer Patients, First Results of Phase 1/2 Trial Indicate

News

Merus’ MCLA-128 antibody has helped patients with HER2-positive metastatic breast cancer who failed several lines of HER2 inhibitor therapy, according to initial results of a Phase 1/2 clinical trial. One ... Read more

May 17, 2017May 17, 2017

Phase 2 Trial to Assess EP-101 Cancer Vaccine-Bavencio Combo Therapy in HER2- Breast Cancer Patients

News

EpiThany says it will test its multi-antigen vaccine EP-101 STEMVAC — in combination with the PD-L1 antibody Bavencio (avelumab) — as a neoadjuvant therapy in breast cancer patients, under a three-way ... Read more

May 16, 2017May 16, 2017

Oncolytics’ Reolysin Receives FDA Fast Track Designation for Metastatic Breast Cancer

News

The U.S. Food and Drug Administration has granted fast track status to Reolysin for treating metastatic breast cancer, according to its developer, Oncolytics Biotech. Fast track accelerates the review of ... Read more

May 12, 2017

CapeRay Wins US Patent for Dual-Mode Imaging System to Detect Breast Cancer

News

CapeRay has received a U.S. patent for its dual-mode breast imaging system, which combines X-rays and ultrasounds in a single device. It is the second patent the system has received. The first was ... Read more

May 11, 2017May 11, 2017

FDA Approves Kisqali Femara Co-Pack to Treat Subset of Advanced Breast Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has approved Novartis Oncology‘s Kisqali Femara Co-Pack for to treat postmenopausal women with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer. The Co-Pack, which includes ... Read more

Pin It on Pinterest